Exploring the Impact of Cemiplimab and Pembrolizumab in Cutaneous Squamous Cell Carcinoma

from Oncology Data Advisor · host i3 Health

In honor of Melanoma Awareness Month, Dr. Shaheer Khan, Assistant Professor of Medicine at Columbia University Irving Medical Center, shares the promising results of two recent trials of cemiplimab and pembrolizumab for cutaneous squamous cell carcinoma, explains future directions in the treatment of patients who are ineligible for immunotherapy, and offers advice for members of the multidisciplinary cancer care team who are treating patients with this disease.

Episode metadata supplied by the publisher feed · Published May 13, 2022

Embed this episode

Attribution link and audio player

NOW PLAYING

Exploring the Impact of Cemiplimab and Pembrolizumab in Cutaneous Squamous Cell Carcinoma

0:00 17:02

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Oncology Data Advisor?

This episode is 17 minutes long.

When was this Oncology Data Advisor episode published?

This episode was published on May 13, 2022.

Can I download this Oncology Data Advisor episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!